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The incorporation of poly(ethylene glycol) (PEG)-conjugated lipids in lipid-based carriers substantially prolongs the circulation lifetime of
liposomes. However, the mechanism(s) by which PEG-lipids achieve this have not been fully elucidated. It is believed that PEG-lipids mediate
steric stabilization, ultimately reducing surface-surface interactions including the aggregation of liposomes and/or adsorption of plasma proteins.
The purpose of the studies described here was to compare the effects of PEG-lipid incorporation in liposomes on protein binding, liposome-
liposome aggregation and pharmacokinetics in mice. Cholesterol-free liposomes were chosen because of their increasing importance as liposomal
delivery systems and their marked sensitivity to protein binding and aggregation. Specifically, liposomes containing various molecular weight
PEG-lipids at a variety of molar proportions were analyzed for in vivo clearance, aggregation state (size exclusion chromatography, quasi-elastic
light scattering, cryo-transmission and freeze fracture electron microscopy) as well as in vitro and in vivo protein binding. The results indicated
that as little as 0.5 mol% of 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine (DSPE) modified with PEG having a mean molecular weight of
2000 (DSPE-PEG2000) substantially increased plasma circulation longevity of liposomes prepared of 1,2-distearoyl-sn-glycero-3-phosphatidylcho-
line (DSPC). Optimal plasma circulation lifetimes could be achieved with 2 mol% DSPE-PEG2000. At this proportion of DSPE-PEG2000, the
aggregation of DSPC-based liposomes was completely precluded. However, the total protein adsorption and the protein profile was not influenced
by the level of DSPE-PEG2000 in the membrane. These studies suggest that PEG-lipids reduce the in vivo clearance of cholesterol-free liposomal
formulations primarily by inhibition of surface interactions, particularly liposome-liposome aggregation.
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Two factors are of paramount importance in the development
of liposomal drug delivery carriers for intravenous use:
liposome circulation lifetime and the release of encapsulated
contents at a rate optimized for efficacy and/or toxicity
endpoints. The presence of poly(ethylene glycol) (PEG) on
the liposome exterior surface, typically achieved by formulation
with PEG-modified lipids, is well known to significantly
enhance liposome circulation lifetime [1–5]. The significance
of the addition of PEG-modified lipids led to the realization of
longer circulation half-lives that could facilitate higher levels of
drug accumulation within sites of tumor growth [6–8]
associated with improved antitumor activity [9–11].
The mechanisms governing these PEG-lipid mediated effects
remain controversial. The most widely accepted hypothesis to
explain the ability of PEG to prolong circulation time of
liposomes is based on “steric stabilization” [12–16] that can
lead to reductions in liposome aggregation [2,17] and plasma
protein adsorption [18,19]. Evidence for this hypothesis has
included measurements of the repulsive pressure between lipid
membranes in the presence and absence of surface grafted
polymers, which demonstrated that there was a larger
interbilayer spacing (4 nm) in membranes modified with
polymers as compared to unmodified bilayers [20]. Kenworthy
et al. analyzed electron density profiles to show the distance
between apposing DSPC/DSPE-PEG lipid bilayers varied as a
function of the concentration of PEG-lipid in the bilayer and
size of the grafted PEG chain. The extension of the PEG chain
from the bilayer surface was 1.0, 2.8, 6.0 and 10.0 nm for PEGs
with average molecular weights of 350, 750, 2000 and 5000,
respectively [14].
Although some evidence suggests that PEG on liposome
surfaces can reduce specific protein interactions [21,22], other
studies have indicated that the clearance of liposomal formula-
tions from the circulation is not correlated with total plasma
protein binding to liposomes [23]. In view of the uncertainties
regarding the mechanism by which PEG-lipid confers steric
stabilization to liposomes, the research described here compares
surface–surface interactions, including self-association (aggre-
gation) and plasma protein adsorption, in cholesterol-free
liposomes. We have chosen to perform these studies in
cholesterol-free liposomes for two reasons. First, cholesterol-
free liposomes have recently been recognized as an important
new class of lipid-based drug delivery vehicles. Typically, the
addition of cholesterol is viewed as essential for the generation
of stable formulations of hydrophilic drugs. However, the
studies of Dos Santos et al. [24] demonstrated that removal of
cholesterol was associated with dramatic improvements in
retention of the hydrophobic anthracycline idarubicin [24].
Interestingly, the liposomal formulations prepared with gel
phase lipids such as DSPC (Tc=55 °C) and surface stabilizing
PEG-modified lipids exhibited long plasma circulation life-
times, essentially identical to sterically stabilized cholesterol-
containing liposomes. These results place a far greater
importance on the role of PEG-lipids than cholesterol in
governing the fate of intravenously administered liposomalformulations. Secondly, it is generally believed that cholesterol
is a liposome “stabilizing” component which causes a reduction
of protein binding following intravenous injection as well as an
enhanced plasma circulation lifetime. Therefore, it was believed
that the absence of cholesterol from these formulations would
facilitate the evaluation of PEG-modified lipids on protein
adsorption to the liposome surface and on liposome–liposome
aggregation.2. Materials and methods
2.1. Materials
1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC) and (DSPE)-con-
jugated poly(ethylene glycol) lipids (PEG average molecular weights 350, 550,
750, 2000 and 5000) were obtained from Avanti Polar Lipids, Inc. (Alabaster,
AL, USA). Cholesterol (CH) was obtained from the Sigma-Aldrich Canada Ltd.
(Oakville, ON, Canada). 3[H]-cholesteryl hexadecyl ether (CHE) (51 Ci/mmol)
and 14[C]-CHE (50.6 mCi/mmol) were obtained from PerkinElmer, Inc.
(Boston, MA, USA). 3[H]-DSPE-PEG2000 was custom synthesized by Northern
Lipids Inc. (Vancouver, BC, Canada). HEPES (N-[2-hydroxyethyl] piperazine-
N′-[2-ethanesulfonic acid]), citric acid, Sephadex G-50 (medium), Sepharose
CL-4B beads and all other chemicals were obtained from Sigma-Aldrich Canada
Ltd. (Oakville, ON, Canada). Picofluor-15 scintillation fluid was obtained from
Packard Bioscience (Groningen, The Netherlands).
2.2. Liposome preparation
All liposome formulations were prepared by the extrusion technique [25,26].
Briefly, the specified lipids were dissolved in chloroform and mixed together in
a test tube at the indicated molar ratios. 3[H]-CHE was added as a non-
exchangeable, non-metabolizable lipid marker [27,28]. The chloroform was
evaporated under a stream of nitrogen gas and the sample was placed under high
vacuum overnight to remove residual solvent. The lipid films were hydrated in
HBS by gentle mixing and heating. When preparing cholesterol-containing
formulations, these were also subjected to five cycles of freeze (liquid nitrogen)
and thaw (65 °C) prior to extrusion. Multilamellar vesicles (cholesterol-free and
cholesterol-containing) were passed 10 times through an extruding apparatus
(Northern Lipids Inc., Vancouver, BC, Canada) containing two stacked 100 nm
Nucleopore® polycarbonate filters (Northern Lipids Inc., Vancouver, BC,
Canada). The mean diameter and size distribution of the liposome preparations
were analyzed by a NICOMP model 270 submicron particle sizer (Pacific
Scientific, Santa Barbara, CA, USA) operating at 632.8 nm, and were typically
100±30 nm in the volume-weighting mode.
2.3. Pharmacokinetic analysis
Balb/c mice (breeders) weighing 20–22 g, were purchased from Charles
River Laboratories (St. Constant, QC, Canada) and then bred in-house. Mice
were housed in microisolator cages and given free access to food and water.
All animal studies were conducted according to procedures approved by the
University of British Columbia's Animal Care Committee and in accordance
with the current guidelines established by the Canadian Council of Animal
Care.
The plasma elimination of liposomes containing trace quantities of 3[H]-
CHE radiolabel was assessed. In brief, Balb/c mice were administered
intravenously, into the lateral tail vein, with liposomes at a lipid dose of
165 μmol/kg. At various time points up to 24 h after drug administration, blood
was collected by tail nick (collected in microfuge tubes) or cardiac puncture
(collected in liquid EDTA coated tubes) and centrifuged at 1000×g for 10 min to
isolate the plasma fraction. Lipid concentration was subsequently measured by
liquid scintillation counting. Plasma area-under-the-curve values were calcu-
lated using WinNonlin pharmacokinetic software (Version 1.5, Pharsight Corp.,
Mountain View, CA). Biodistribution studies of tissue samples and plasma
correction factors were applied as previously published [29].
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For freeze-fracture analysis, aliquots of each liposome preparation were
mixed with glycerol (to final proportion of 25% v/v) as a cryoprotectant and
incubated for 30 min. A small droplet of sample was loaded into the well of a
Balzers gold freeze fracture specimen holder (BAL-TEC, BU 012 130-T) such
that the sample protruded 2 mm above the top of the holder. The holder was
inverted and plunged into liquid propane (cooled to ∼−160 °C with liquid
nitrogen). After immersion, specimen were transferred to dry liquid nitrogen
cooled cryovials and stored in liquid nitrogen. For fracturing and replica
preparation, specimen were loaded onto the freeze fracture specimen table under
liquid nitrogen, then inserted into a Balzers BAF 060 freeze fracture apparatus
equipped with a quartz thin-film monitor (BAL-TEC, Balzers, Liechtenstein,
Germany), which had been pre-cooled to −170 °C. Specimen were then warmed
to −110 °C to −115 °C and fractured without etching, followed immediately by
replication using unidirectional platinum/carbon shadowing at 45° (2.3 nm) and
carbon backing at 90° (2.2 nm). The holders containing the replicated samples
were removed from the freeze fracture unit, thawed and slid gently into
commercial bleach in the wells of a porcelain spotting plate. Cleaning required
48 h in bleach at room temperature, with 3 changes of bleach. Replicas were then
washed extensively with NANOpure water (Barnstead/Thermolyne, Dubuque,
IA, USA) mounted on Formvar-coated 100/hex copper grids and viewed at an
accelerating voltage of 80 kV in a Hitachi H7600 transmission electron
microscope (Tokyo, Japan) equipped with an AMTAdvantage HR digital CCD
camera (Advanced Microscopy Techniques Corp., Danvers, MA, USA).
2.5. Size exclusion chromatography
For evaluating the mean diameter and structure of liposomes containing
increasing concentrations of DSPE-PEG lipids, DSPC/DSPE-PEG2000 (20 mM
lipid) liposome formulations were dually radiolabeled with 14[C]-CHE and 3[H]-
DSPE-PEG2000 and passed down a Sepharose CL-4B column (40 ml,
22 cm×1.5 cm) at a flow rate of 0.5 ml/min. 3[H]-DSPE-PEG2000 micelles
were passed down the Sepharose CL-4B column as a reference for the elution
volume of pure micelles.
2.6. Protein binding assays
For in vivo protein binding studies, Balb/c mice were administered
intravenously with various liposomal formulations, via the lateral tail vein, at
a lipid dose of 165 μmol/kg. Five minutes after injection, blood samples were
obtained by cardiac puncture. Serum was isolated from whole blood by allowing
the blood to clot for 30 min then centrifuging for 10 min at 1000×g. Liposomes
with adsorbed proteins were separated from free proteins by analyzing a 500 μl
aliquot of serum by size exclusion chromatography as described below. For in
vitro protein binding studies, various liposomal formulations (0.7 μmol lipid)
were incubated with mouse serum (400 μl) for 10 min 37 °C. This lipid
concentration was chosen to approximate the in vivo lipid concentration after
liposome administration at 165 μmol lipid/kg, assuming a blood volume of 2 ml
per 22 g mouse and a hematocrit of 0.48. Liposomes with adsorbed proteins
were separated from free proteins by analyzing a 500 μl aliquot of serum by size
exclusion chromatography as described below.
The size exclusion method for separation of liposome-adsorbed proteins
from free proteins was modified from previous reports [4,30–32]. The in vivo
and in vitro samples described above were separated by size exclusion
chromatography on a Sepharose CL-4B column (40 ml, 22 cm×1.5 cm) eluted
with HBS (pH 7.4) at a flow rate of 0.5 ml/min and the collection of 0.5 ml
fractions. In the initial analysis, each fraction was assayed for lipid concentration
by liquid scintillation counting and protein concentration using 20 μl for micro
BCA assay. Based on these results, and providing that there was good separation
between lipid and bulk plasma protein peaks, 3–5 fractions were pooled from
the lipid peak. These pooled fractions were then re-assayed for lipid and protein
as follows. Due to the fact that lipid tends to interfere with many protein assays,
a lipid extraction was performed to separate the protein for quantification by
micro-BCA acid assay, as described previously [33]. Briefly, 400 μl of cold
methanol was added to 100 μl of pooled sample (in triplicate) in 1.5 ml
microfuge tubes. The samples were vortexed and centrifuged at 9000×g for3 min. 200 μl of chloroform was added to the samples, followed by vortexing
and centrifugation at 9000×g for 3 min. 300 μl of H20 was added to each sample,
followed by vortexing and centrifuging at 9000×g for 4 min. The upper phase
was discarded (approximately 700 μl) from this two-phase system then 300 μl of
methanol was added to the lower phase and the sample was subsequently
vortexed and centrifuged at 9000×g for 4 min. Most of the supernatant was
removed and the residual supernatant was dried down with nitrogen for 2 h.
Protein was present as a dry pellet at the bottom of the microfuge tube and was
resuspended in 110 μl water at 50 °C–60 °C. For determination of the protein
concentration, 110 μl of micro-BCA working reagent (Pierce, Rockford, IL,
USA) was added to each sample and measured at 570 nm on MRX microplate
reader (Dynex Technologies, Inc., Chantilly, VA, USA) and was compared to a
bovine serum albumin standard curve. For the quantification of lipid, 20 μl
aliquots (in triplicate) of pooled sample were measured by liquid scintillation
counting then the amount of lipid in the recovered sample was calculated from
the specific activity. Protein binding values (PB) were measured as μg protein/
μmol liposomal lipid; values represented the mean and standard deviations from
three experiments.
2.7. Electrophoretic analysis of liposome-bound proteins
After the separation of liposomes from bulk plasma proteins and delipidation
(lipid extraction/protein precipitation) as described above, samples were
solubilized in SDS-reducing buffer (0.0625 M Tris–HCl, 10% (v/v) glycerol,
2% (w/v) SDS, 5% (v/v) β-mercaptoethanol, 0.125% (w/v) bromophenol blue)
heated to 95 °C, cooled and centrifuged. Approximately 0.1 μmol of total lipid
was loaded on a SDS-polyacrylamide gel (PAGE) prepared on a Mini Protean II
apparatus (Bio-Rad Laboratories, Richmond, CA, USA). Proteins were
visualized by silver staining. Silver stain SDS-PAGE molecular weight
standards (Bio-Rad Laboratories, Richmond, CA, USA) were used to estimate
the molecular weights of proteins.
2.8. Statistical analysis
A standard one-way analysis of variance (ANOVA) was used to determine
statistically significant differences of the means. For multiple comparisons, post-
hoc analysis using the Tukey–Kramer test was performed. A value of p<0.05
was considered significant.3. Results
3.1. Effect of DSPE-PEG2000 composition on the circulation
lifetime of cholesterol-free liposomes
Pharmacokinetic studies were performed as a functional test
for assessing the effects of different amounts and molecular
weights of surface-grafted PEG on the circulation lifetimes of
DSPC (cholesterol-free) liposomes. The effects of 0.5 to 5 mol
% of DSPE-PEG2000 in DSPC liposomes are shown in Fig. 1.
These data indicate that the addition of DSPE-PEG2000, at
proportions as low as 0.5 mol%, to DSPC liposomes
significantly enhanced liposome circulation longevity. Specifi-
cally, the plasma area-under-the-curve (AUC0–24 h) value for
DSPC liposomes containing only 0.5 mol% of DSPE-PEG2000
was 5.7-fold higher than that for 100 mol% DSPC liposomes.
Further increases in plasma AUC0–24 h were observed as the
DSPE-PEG2000 concentration was increased and reached a
plateau for DSPC liposomes prepared with 2 and 5 mol%
DSPE-PEG2000, with plasma AUC0–24 h values of 41.3 and
45.8 μmol·h·ml−1, respectively (Table 1). The percent of the
injected lipid dose that was remaining in the circulation 24 h
after injection was 30%, 26%, 18% and 13% for liposomes
Fig. 1. The effect of mol%DSPE-PEG2000 proportion on the plasma clearance of
DSPC liposomes. (A) Liposome formulations composed of DSPC and varying
amounts of DSPE-PEG2000; 0 mol% (□), 0.5 mol% (▽), 1 mol% (△), 2 mol%
(○), and 5 mol% (◇) were administered as a single i.v. bolus injection of 165
µmol/kg total lipid in female Balb/c mice (injected dose=3.3 µmol lipid/ml
plasma). (B, C) DSPC/DSPE-PEG2000 (99:1 mol ratio) liposomes were
administered as a single i.v. bolus injection of 165 µmol/kg total lipid in male
Balb/c mice and (B) plasma lipid concentrations and (C) lung tissue distribution
was measured. Each data point represents the average total lipid plasma
concentration±standard deviation of 3 mice.
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All of these values were significantly (p<0.05) higher than
those observed for liposomes prepared in the absence of added
DSPE-PEG2000. Further pharmacokinetic analysis was per-
formed with DSPC liposomes containing 1 mol% PEG lipids tofurther dissect the elimination curve. A similar decrease in
plasma lipid concentration was observed between 15 min and
1 h, followed by an increase at the 2 h time point (Fig. 1B).
Biodistribution studies indicated that a peak of 0.74 μmol lipid/
gram lung tissues occurred 15 min following injection (Fig.
1C). Lipid accumulation in the MPS organs, including the liver
and spleen peaked at 2 h post injection with 2.23 μmol lipid/
gram and 2.59 μmol lipid/gram, respectively (data not shown).
The effect of the molecular weight of the PEG moiety
conjugated to DSPE on the circulation longevity of cholesterol-
free liposomes was used as a functional assay of surface
protection. Balb/c mice were injected with DSPC liposomes
containing either 2 mol% or 5 mol% of DSPE-PEG where the
mean PEG molecular weight was 350 (DSPE-PEG350), 550
(DSPE-PEG550), 750 (DSPE-PEG750), or 2000 (DSPE-
PEG2000). Although DSPC liposomes containing 5 mol%
(Fig. 2A) or 2 mol% (Fig. 2B) of DSPE-PEG2000 had higher
concentrations of liposomal lipid in the plasma 24 h after i.v.
administration, the differences between these liposomes and
those prepared with lower molecular weight PEGs were not
significant. That is, liposomes containing DSPE-PEG750,
DSPE-PEG550, or DSPE-PEG350 had similar circulation life-
times regardless of whether the level of incorporation was 5 mol
% or 2 mol%.
3.2. In vitro and in vivo adsorption of proteins to liposomes
Further studies were conducted with the intent of correlat-
ing pharmacokinetic behaviour of liposomal formulations
having a range of different clearance characteristics with
protein binding and/or aggregation results. In the absence of
distinct pharmacokinetic effects attributable to the low
molecular weight PEGs (Fig. 2), we have used DSPC-based
liposomes containing 0–5 mol% of DSPE-PEG2000 for the
correlation to protein binding and aggregation results.
Protein binding studies were completed using liposomes
exposed to plasma proteins in vivo and in vitro. For these
studies, the recovered plasma was fractionated on a size
exclusion column to separate liposome-associated proteins from
free, bulk, protein. Fig. 3 shows a typical elution profile of
liposomes and bulk plasma proteins from the size exclusion
column. The peak fractions of the eluted liposomes, at elution
volumes between 14 and 16 ml, were pooled and the lipid was
extracted to avoid interference in the micro-BCA assay used to
measure protein. For the in vivo studies, the recovery of
liposomes from the serum at 5 min after intravenous injection
was between 75% and 95%.
The protein binding (PB) values, given as μg of protein
bound per μmol lipid, for DSPC liposomes prepared with
increasing amounts of DSPE-PEG2000 are summarized in Table
1. PB values obtained with cholesterol-free liposomes were
compared to conventional liposomes (DSPC/CH; 55/45 mole
ratio) and to sterically stabilized (DSPC/CH/PEG; 50/45/5
mole ratio) liposomes. The data presented in Table 1 emphasize
three points. First, the PB values determined from liposomes
incubated in vitro were essentially identical (p>0.05) to those
determined for liposomes recovered after in vivo incubation.
Table 1
Summary of protein binding values to liposomes determined using in vitro and in vivomethods, calculated liposome surface coverage provided by PEG and clearance
properties of liposomes from the circulation of mice
Formulation a Protein Binding (PB) (μg protein/
μmol lipid)
PEG coverage (%) b AUC0–24 h (μg·h/ml)
In vitro c In vivo d
DSPC N/D e N/D e 0 3.9
DSPC/DSPE-PEG2000 (99.5/0.5) N/D
e N/D e N/D e 22.1
DSPC/DSPE-PEG2000 (99/1) 35.4 (10.9) 42.6 (6.1) N/D
e 33.2
DSPC/DSPE-PEG2000 (98/2) 39.4 (5.4) N/D
e 100 41.3
DSPC/DSPE-PEG2000 (95/5) 39.9 (6.6) 29.5 (6.6) 100 45.8
DSPC/DSPE-PEG750 (98/2) N/D
e N/D e 43 32.6
DSPC/DSPE-PEG750 (95/5) N/D
e N/D e 100 36.1
DSPC/DSPE-PEG550 (98/2) N/D
e N/D e 31 33.9
DSPC/DSPE-PEG550 (95/5) N/D
e N/D e 79 45.6
DSPC/DSPE-PEG350 (98/2) N/D
e N/D e 17 30.8
DSPC/DSPE-PEG350 (95/5) N/D
e N/D e 45 41.1
DSPC/CH (55/45) 29.9 (5.5) 29.9 (5.7) 0 23.3
DSPC/CH/DSPE-PEG2000 (50/45/5) 34.2 (8.7) 23.8 (3.6) 100 44.7
a Liposome formulations with molar ratios of lipid components indicated in parentheses.
b From Ref. [12].
c For in vitro groups, data represent the means of 3–5 experiments (±standard deviation).
d For in vivo groups, data represent the means of 3 mice (±standard deviation).
e N/D, indicates not determined.
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or in vivo approaches can be used to evaluate protein
adsorption to liposomes. Second, all liposome formulationsFig. 2. The effect of PEG-lipid molecular weight on the plasma clearance of
DSPC liposomes. Liposomal formulations were composed of DSPC containing
5 mol% (A) and 2 mol% (B) PEG-lipids of varying molecular weights. Symbols
represent DSPE-PEG2000 (●), DSPE-PEG750 (■), DSPE-PEG550 (▲), or DSPE-
PEG350 (▼). Unfilled squares indicate DSPC (100 mol%) liposomes. Female
Balb/c mice were administered a single i.v. bolus injection of 165 µmol/kg total
lipid (injected dose=3.3 µmol lipid/ml plasma). Each data point represents the
average total lipid plasma concentration±standard deviation for 3 mice.evaluated, regardless of the proportion of PEG-modified lipids
in the preparations, had comparable in vitro PB values. That is,
the PB values ranged from 29.9 (±5.5) for DSPC/CH (55/45
mole ratio) liposomes to 39.9 (±6.6) for DSPC/DSPE-PEG2000
(95/5 mole ratio). Third, there was no discernible correlation of
in vitro PB values with the known clearance characteristics
(Fig. 1) of the liposomes. Specifically, the DSPC/DSPE-
PEG2000 (99/1 mole ratio) liposomes (PB values of 35.4±10.9)
were eliminated more rapidly from the circulation than were
liposomes containing either with 2 mol% (PB values of 39.4±Fig. 3. Separation of DSPC/DSPE-PEG2000 (95:5 mol/mol) liposomes from bulk
mouse plasma proteins by size exclusion chromatography. Mouse serum and
liposomes were incubated at 37 °C for 10 min. The mixture was passed down a
Sepharose CL-4B column (40 ml, 22 cm×1.5 cm) with HBS at a flow rate of
0.5 ml/min. Fractions (0.5 ml) were collected and assayed for liposomal lipid
concentration (●) by liquid scintillation counting and for protein concentration
(□) by micro-BCA assay. Under these conditions, optimal separation of
liposomes and bulk serum proteins was achieved. The peak fractions, indicated
between the arrows, were pooled to determine the amount of plasma protein
bound to liposomes.
Fig. 4. PAGE analysis of liposome-associated plasma proteins. Protein was
extracted by precipitation from column-purified liposomes (0.1 µmol total
lipid) and separated on 7.5% polyacrylamide gels. Proteins were visualized by
silver stain. Lane 1, high molecular weight markers; Lane 2, total mouse
serum (200× diluted); Lane 3, DSPC/CH/DSPE-PEG2000 (50:45:5 mol ratio);
Lane 4, DSPC/DSPE-PEG2000 (99:1 mol ratio); Lane 5, DSPC/DSPE-PEG2000
(95:5 mol ratio).
Fig. 5. The effect of DSPE-PEG2000 on liposome aggregation as determined by QEL
represent the standard deviation of the liposome population) of DSPC liposomes (with
filters was measured by QELS analysis over a 30-min time course. (B) The effect of D
containing 2, 5 and 15 mol% DSPE-PEG2000 was determined by QELS (bars repre
15 mol% DSPE-PEG2000 exhibited a bimodal distribution with % of total liposome p
DSPC liposomes containing 0 (upper panel), 2 (second panel), 5 (third panel) or 15
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Therefore, it is concluded from these results that protein
binding in these formulations does not correlate with liposome
clearance from the circulation after intravenous administration.
Although the PB values suggest that PEG incorporation does
not have a significant impact on non-specific plasma protein
adsorption, it is possible that the binding of specific protein
types were different, a parameter that could be qualitatively
assessed by PAGE analysis of the liposome-associated proteins.
The protein binding profiles were investigated by recovering
plasma proteins that were bound to 0.1 μmol DSPC/CH/DSPE-
PEG2000 (50/45/5 mole ratio), DSPC/DSPE-PEG2000 (99/1
mole ratio) and DSPC/DSPE-PEG2000 (95/5 mole ratio)
liposomes. Subsequently the isolated proteins were separated
on 7.5% acrylamide gel and visualized by silver stain. A
representative study is shown in Fig. 4. The profiles suggest that
proteins exhibiting molecular weights similar to serum albumin
(mol. wt. ∼66,000) and IgG (mol. wt.=150,000) were bound at
comparable levels for DSPC/CH/DSPE-PEG2000 (50/45/5 mole
ratio) and DSPC/DSPE-PEG2000 (99/1 and 95/5 mole ratios)
liposomes and there were no readily identifiable differences inS and freeze-fracture analysis. (A) The apparent mean liposome diameter (bars
out DSPE-PEG) following extrusion through two stacked 100-nm polycarbonate
SPE-PEG2000 on the diameter of DSPC liposomes. The size of DSPC liposomes
sent the standard deviation of the liposome population). Liposomes containing
opulation indicated in parentheses. (C) Freeze-fracture electron micrographs of
(lower panel) mol% DSPE-PEG2000. Bars indicate 100 nm.
Fig. 6. Size exclusion chromatography analysis of DSPC liposomes prepared
with 5–20 mol% DSPE-PEG2000. DSPC liposomes (20 mM lipid) containing
5–20 mol% DSPE-PEG2000 were dual radiolabeled with tracer quantities of
14[C]-CHE and 3[H]-DSPE-PEG2000 were prepared and subsequently passed
down a Sepharose CL-4B column (40 ml, 22 cm×1.5 cm) at a flow rate of
0.5 ml/min. The formulations containing varying amounts of PEG conjugated
lipids are indicated by the following symbols, 5 mol% (●), 10 mol% (○),
15 mol% (▲), 20 mol% (□). 3[H]-DSPE-PEG2000 micelles were passed down
the column as a control (◆). Inset: Representative cryo-transmission electron
micrographs of mixed micelles composed of DSPC and 10 or 20 mol% DSPE-
PEG2000. Bar represents 100 nm.
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separation and protein visualization techniques will be required
to determine minor (but perhaps significant) changes in protein
binding that were not detected by the methods used here.
Collectively, the most significant conclusion from these protein
binding studies suggest that proteins adsorb onto the surface of
liposomes at comparable levels and in comparable patterns
regardless of liposome composition.
3.3. Effect of DSPE-PEG on aggregation of cholesterol-free
liposomes
The effects of PEG-lipid incorporation on liposome diameter
and aggregation behaviour were determined by QELS and
freeze-fracture electron microscopy. For DSPC liposomes
lacking DSPE-PEG2000, a time-dependent increase of the
measured size occurred during the 30 min after liposome
preparation by extrusion (Fig. 5A). The increase of the apparent
liposome size was immediate, as indicated by an average
particle diameter at 1 min after extrusion of 164.7±96 nm (chi-
squared 0.435) (Fig. 5A). The measured size further increased
to 263.8±216.9 nm (chi-squared 2.990, suggestive of a
multimodal size distribution) after 32 min of incubation at
room temperature. When these liposomes were heated to 65 °C,
the size returned to mean diameters between 100 and 200 nm,
suggesting that aggregation/self-association rather than fusion
caused the vesicle size increase. This interpretation was directly
confirmed by examination of DSPC liposomes using freeze-
fracture electron microscopy (Fig. 5C, upper panel) showing the
presence of large aggregates comprised of multiple liposomes
having individual diameters of approximately 100 nm. These
independent methods both support the conclusion that lipo-
some–liposome association occurs in the DSPC preparations
lacking DSPE-PEG2000.
In contrast to the results described above, DSPC liposomes
containing either 2 mol% or 5 mol% DSPE-PEG2000 had mean
diameters of between 95 and 100 nm (with a standard deviation
of <20% and a chi-squared value of 0.250 indicative of a
unimodal vesicle population) (Fig. 5B). The size of these
liposomes were directly confirmed by freeze-fracture electron
microscopy showing discrete, non-aggregrated, liposomes with
mean diameters of approximately 100 nm (Fig. 5C, two middle
panels). When DSPC liposomes were prepared with 15 mol%
DSPE-PEG2000, QELS analysis indicated a bimodal distribution
with structures exhibiting a mean diameter of 40 nm (54% of the
liposome population) and 125 nm (46% of the liposome
population). The existence of the smaller vesicle population
represents bilayer disks and/or mixed micelles and is consistent
with the bilayer destabilizing effects of PEG-modified lipids
when incorporated at high levels. Freeze fracture electron
micrographs of these formulations (Fig. 5C, last panel) suggest
that there were fewer liposomes present within a given fracture
plane when compared to samples prepared from liposomes
composed of 2 and 5 mol% DSPE-PEG2000 (note that all
samples were prepared with 10 mM total lipid concentration).
Previous studies have indicated that it is difficult to distinguish
micelles by freeze fracture techniques due to the lack of afraction plane between an inner and outer leaflet which
comprises the lipid bilayer [34].
To further assess whether the presence of DSPE-PEG2000 at
levels in excess of 5 mol% led to the formation of mixed
micelles, DSPC liposomal formulations composed of 5–
20 mol% DSPE-PEG2000 were analyzed by size exclusion
chromatography (Fig. 6). The elution profiles were compared
to those observed using 100 nm DSPC/cholesterol liposomes
and to pure DSPE-PEG2000 micelles. For size exclusion
chromatography studies, dual-labeled DSPC liposomes with
increasing levels of DSPE-PEG2000 were passed down a
Sepharose CL-4B column at a flow rate of 0.5 ml/min. One
peak eluted between 24 and 30 ml for liposomes composed of
5 mol% PEG, the same elution profile observed for control
DSPC/cholesterol. liposomes. For formulations containing
10 mol% DSPE-PEG2000 the bulk of the lipid eluted between
24 and 30 ml (consistent with liposomes), however there was
significant tailing in the elution profile. This tailing was
increased as the amount of DSPE-PEG2000 increased and
appeared as a distinct peak in fraction 32–35 ml for those
formulations prepared using 20 mol% DSPE-PEG2000. It
should be noted that the second peak was distinct from that
observed when using pure PEG micelles, which eluted in
fractions 48–62 ml. For all elution peaks, both 3[H]-PEG-
lipids and 14[C]-CHE were present, suggesting that all liposome
populations represented by the different elution peaks contained
both the bulk phospholipids and PEG components.
Fig. 7. Relationship between calculated surface coverage of liposomes by PEG
and the observed clearance of liposomes from the circulation. Figure shows a
scatter plot of the PEG coverage (%) vs. AUC0–24 h values from Table 1 for the
following cholesterol-free liposome formulations: 1, DSPC; 2, DSPC/DSPE-
PEG350 (98:2); 3, DSPC/DSPE-PEG550 (98:2); 4, DSPC/DSPE-PEG750 (98:2);
5, DSPC/DSPE-PEG350 (95:5); 6, DSPC/DSPE-PEG550 (95:5); 7, DSPC/DSPE-
PEG2000 (95:5); 8, DSPC/DSPE-PEG2000 (98:2); 9, DSPC/DSPE-PEG750 (95:5).
The line represents the linear regression for these points and has a correlation
coefficient, r2, of 0.56.
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DSPC liposomes prepared using 10 and 20 mol% DSPE-
PEG2000, cryo-transmission electron micrographs of these
samples were prepared. Representative micrographs of DSPC
liposomes prepared with 10 mol% and 20 mol% DSPE-PEG2000
(Fig. 6 inset) indicated that small structures were present. In
particular, bilayer disks (indicated by many “edge on”
orientations) were evident as described previously by Edwards
et al. for cholesterol-containing systems [35] and Ickenstein et
al. for cholesterol-free systems [36]. Taken together, these
studies indicate that DSPC liposomes, incorporating between 2
and 5 mol% DSPE-PEG2000, can form stable preparations that
exhibit extended circulation lifetimes. Bilayer disks or mixed
micelles were present when the amount of DSPE-PEG2000 was
equal to or greater than 10 mol%.
4. Discussion
The incorporation of surface grafted PEGs on liposomes
has had a significant impact on the development of liposomal
technology for the delivery of chemotherapeutic agents. In
spite of the widespread use of PEG-conjugated lipids in
liposomal formulations, there remains a great deal of specu-
lation about the mechanism(s) by which surface-exposed
PEGs increase the circulation lifetime of i.v.-administered
liposomes. It is generally believed that this effect can be
attributed to PEG's ability to reduce plasma protein binding;
an observation originally documented for solid surfaces with
surface-grafted PEG moieties [37,38]. A reduction of plasma
protein adsorption to the liposome surface is believed to
minimize the recognition of injected liposomes by cells of the
mononuclear phagocytic system (MPS), which are known to
play a significant role in the elimination of particulate delivery
systems from the blood compartment.
In recent years, there has been a growing body of evidence
suggesting that PEG does not reduce plasma protein adsorption
on liposomes [32,39]. An alternative mechanism of action of the
PEGs could be via the inhibition, or reduction, of liposome–
liposome aggregation and maintenance of the injected liposome
population as discrete particles with a small (about 100 nm)
diameter optimized for prolonged circulation lifetime [40
Mayer, 1993 #344]. In this study, a functional pharmacokinetic
assay, based on PEG-mediated alterations in the circulation
lifetime of DSPC liposomes following i.v. administration in
mice, was used to measure how the proportion and molecular
weight of PEG conjugated to DSPE influenced the behaviour of
DSPC liposomes. The results from this functional assay were
correlated with studies on the effects of PEG on surface–surface
interactions including plasma protein adsorption and liposome
aggregation.
Previous studies of the plasma elimination of intravenously-
injected liposomes have suggested that the PEG lipid anchor
[41], PEG density [42], PEG molecular weight [43,44] affect
the circulation longevity of cholesterol-containing liposomes
[9]. However, in the pharmacokinetic studies reported here,
there were no significant differences in the circulation longevity
of cholesterol-free liposomes containing 2 mol% and 5 mol%(Fig. 1) to 10 mol% (data not shown) of DSPE-PEG2000 or in
liposomes containing 5 mol% PEG having molecular weights
between 350 and 2000. There were no additional improvements
in the circulation longevity of liposomes prepared with PEG
(molecular weight 2000) at concentrations greater than 2 mol%;
a polymer concentration that is argued to provide sufficient
surface coverage for a 100 nm liposome [23]. Assuming that the
PEG-lipids homogenously distribute within the DSPC lipid
matrix, surface coverage calculations for DSPC/DSPE-PEG2000
liposomes [23] indicate that 100% surface coverage of a 100 nm
liposome is obtained with both 2 mol% DSPE-PEG2000 and
5 mol% DSPE-PEG750. However, as indicated in Fig. 2A,
liposomes containing 5 mol% DSPE-PEG550 or DSPE-PEG350
had similar elimination profiles (AUC0–24 h values of 45.6 and
41.1 μg·h/ml, respectively, Table 1), yet calculations estimating
surface coverage with these shorter length polymers would be
quite different (79% and 45%, respectively, Table 1). For
example, liposomes composed of 2 mol% DSPE-PEG350 have
only 17% surface coverage, yet had a 7.9-fold higher plasma
AUC0–24 h compared to that for 100 mol% DSPC liposomes
(Table 1) [45,46].
The correlation between surface protection provided by PEG
and prolonged circulation lifetime is shown in Fig. 7. This
scatter plot of calculated surface coverage values vs. measured
AUC0–24 h values (from Table 1) for cholesterol-free liposomes
containing various PEG-PE molecular species shows a weak
(r2 =0.56) relationship. Taken together, these data clearly
indicate that several formulations of DSPC liposomes have
surface area coverage less than 100% but which also have
prolonged circulation lifetimes (Figs. 1 and 2). We interpret these
results to suggest that complete surface coverage is not required
for PEG to cause increased circulation time of liposomes and
that other PEG-mediated effects are involved.
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influenced by the presence of 0–5 mol% DSPE-PEG2000, in
spite of significant differences in the liposome clearance from
the circulation (Fig. 1), the role of protein binding in mediating
liposome clearance must be reconsidered. Specifically, the
adsorption of total (Table 1) and specific (Fig. 4) serum
proteins were not significantly affected by the presence of
either DSPE-PEG or cholesterol, despite significant pharma-
cokinetic differences between these liposomes (Fig. 1). These
studies also demonstrated that liposomal DSPC formulations
with adsorbed proteins (≥35.4 μg protein/μmol lipid) had long
circulation lifetimes. The absolute protein binding values
obtained in these studies correlated well with those determined
in previous studies [47–51]. It was not possible to assess PB
values for a pure DSPC formulation due to problems associated
with liposome aggregation prior to and after mixing with
serum. Overall, these results strongly suggest the absence of a
causal relationship between protein adsorption on the surface of
DSPC-based liposomes and the circulation lifetime of the
liposome. That is, although PEG-containing formulations had
longer circulation lifetimes than liposomes lacking PEG (Figs.
1 and 2) the increase of the circulation lifetime could not be
directly associated with either PEG content or protein binding.
Furthermore, it is apparent that long circulating liposomes or
lipid/DNA complexes [52] have high amounts of protein bound
to their surfaces. It could be interpreted that the liposomes
prepared with DSPE-PEG did not have reduced protein binding
values due to the depletion of the pool of proteins available for
adsorption to the liposome surface, as observed previously
[53]. However, we consider this explanation to be unlikely
since the lipid doses necessary to deplete the available pool of
blood proteins associated with MPS-mediated liposome
clearance [42,53] are much higher than the 165 μmol/kg
(approximately 130 mg/kg) used in this study. Although to
further eliminate the effect of MPS-mediated liposome
clearance, full dose titrations of low PEG containing liposomes
are required. However, we interpret these results to suggest that
PEG-mediated effects distinct from reductions of protein
binding are also involved in the circulation longevity of
PEG-containing liposomes.
An alternative mechanism by which PEG-modified lipids
act to prolong the circulation lifetime of DSPC liposomes is to
sterically preclude interactions that lead to rapid clearance from
blood compartment. This could include a role for PEG in
preventing interaction with Fc receptors or complement
proteins [54,55], directly inhibiting cell uptake and/or
preventing liposome aggregation and subsequent rapid elimi-
nation due to large particle size. The most compelling evidence
for the ability of PEG-lipids to prevent surface–surface
interactions, particularly aggregation, was revealed by freeze-
fracture micrographs and QELS analyses (see Fig. 5). These
studies demonstrate that 100 mol% DSPC liposomes can be
prepared by extrusion methods, but the resulting liposomes
rapidly coalesce and aggregate (Fig. 5A) into larger structures
(Fig. 5C, upper panel). Previous studies have established that
the clearance of liposomal drugs from the circulation is
strongly dependent on the liposome size, with more rapidclearance occurring in liposomes having mean diameters of
>100 nm [40,56]. Structures having greater sizes were
observed for aggregated preparations of 100 mol% DSPC
(Fig. 5A and C, upper panel). It is likely, therefore, that
aggregation of liposomes contributed to the rapid initial phase
of clearance of the DSPC liposomes from the circulation and,
further, that it is possible that liposome aggregation was
increased in the plasma compartment. This is consistent with
the report by Ahl et al. [57] which investigated the role of non-
PEG derivatives of PE on circulation longevity in DSPC
liposomes and showed that aggregation was prevalent in both
rat serum and plasma and, in turn, the liposome aggregation
level was inversely correlated with in vivo circulation lifetimes.
Further, previous studies investigating the effects of PEG on
preventing fusion of dioleoylphosphatidylethanolamine
(DOPE) or didodecylphosphate (DDP) bilayers, also concluded
that the inhibition of fusion was due to PEG-mediated
inhibition of liposome association [58,59]. PEG-lipids
engrafted on liposomes prevent close interactions between
liposomes, effectively ablating attractive Van der Waals short
range forces that promote aggregation [58,59]. Since choles-
terol-free liposomes have a greater tendency to aggregate than
cholesterol-containing liposomes, the effects of short chain
PEGs and low levels of PEG incorporation are much more
apparent in these formulations. It should be noted that Edwards
et al. [35] have shown with cryo-TEM that cholesterol
containing liposomes have a strong tendency to aggregate
and that this aggregation is effectively prevented by incorpora-
tion of PEG-lipids.
In summary, these studies indicated that levels ≤5 mol%
DSPE-PEG2000 can be incorporated into cholesterol-free DSPC
liposomes and have profound effects on their longevity in the
circulation. Although DSPC liposomes containing between 1
and 5 mol% DSPE-PEG2000 had significant differences in their
circulation lifetimes, the protein binding profiles for these
formulations were very similar. In contrast, the addition of
DSPE-PEG2000 prevented the aggregation of DSPC liposomes
and was correlated with prolonged circulation longevity. It is
concluded that the primary effect of PEG-conjugated lipids in
these liposomes is mediated via a PEG-dependent steric barrier
that does not influence protein binding and does not require
100% coverage of the liposome surface.
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